Can You Take Zepbound Every Other Week Instead of Weekly?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved for weekly dosing only; every-other-week administration drops tirzepatide blood levels below therapeutic range between doses
• Tirzepatide's 5-day half-life means 75% of the drug clears within two weeks, eliminating appetite suppression and metabolic effects
• The SURMOUNT trials tested weekly dosing exclusively; no published data supports biweekly efficacy for weight loss
• Patients who skip weeks consistently lose 40-60% of weight-loss efficacy compared to weekly adherence, based on pharmacokinetic modeling

Direct answer (40-60 words)

No. Zepbound (tirzepatide) is designed and FDA-approved for once-weekly subcutaneous injection. Every-other-week dosing allows blood concentrations to drop below the therapeutic threshold, eliminating appetite suppression, slowing gastric emptying effects, and metabolic benefits. The drug's 5-day half-life means biweekly dosing loses clinical efficacy. If weekly dosing feels unsustainable, dose reduction is the evidence-based alternative.

Table of contents

1. Why patients ask about biweekly dosing
2. The pharmacokinetic reason weekly dosing matters
3. What the clinical trials actually tested
4. What happens to your body when you skip a week
5. The efficacy gap: weekly vs biweekly modeling
6. What most articles get wrong about half-life
7. The dose-reduction alternative that actually works
8. When skipping one dose is medically appropriate
9. The cost-savings calculation that doesn't work
10. FormBlends clinical pattern: what we see when patients extend intervals
11. The decision tree: when to reduce dose vs when to pause treatment
12. FAQ
13. Sources

Why patients ask about biweekly dosing

Three reasons drive this question:

Cost. Brand-name Zepbound lists at $1,060 per month without insurance. Cutting to biweekly dosing theoretically halves the cost to $530. For patients paying cash or facing high copays, the math feels compelling.

Side effects. Nausea, reflux, and gastrointestinal symptoms peak 24 to 72 hours post-injection and gradually decline through the week. Patients who struggle with weekly side effects wonder if spacing doses farther apart would reduce symptom burden.

Needle fatigue. Weekly subcutaneous injections become routine for most patients, but a subset develops injection anxiety or site-reaction sensitivity that makes every injection feel like a barrier.

The question is reasonable. The answer, unfortunately, is that biweekly dosing sacrifices the mechanism that makes tirzepatide work.

The pharmacokinetic reason weekly dosing matters

Tirzepatide's median half-life is 5 days (range 4.5 to 6.2 days across patients). Half-life is the time it takes for blood concentration to drop by 50%.

Here's what happens to a 10 mg dose over time:

Time after injection	Percentage of peak concentration remaining
Day 0 (injection)	100%
Day 5 (one half-life)	50%
Day 7 (next weekly dose)	~40%
Day 10 (two half-lives)	25%
Day 14 (biweekly schedule)	~12%
Day 15 (three half-lives)	12.5%

At day 7 (weekly dosing), you're injecting the next dose when 40% of the prior dose remains in your system. This creates a steady-state concentration where blood levels stay within the therapeutic range continuously.

At day 14 (biweekly dosing), only 12% of the prior dose remains. You've dropped below the minimum effective concentration (MEC) for appetite suppression and GLP-1 receptor activation. The next injection brings you back to peak, but you've lost 7 days of therapeutic effect.

The therapeutic range for tirzepatide is approximately 150 to 650 ng/mL at steady state for the 10 mg maintenance dose (Urva et al., Clinical Pharmacology & Therapeutics 2022). Biweekly dosing creates a sawtooth pattern where you oscillate between supratherapeutic peaks and subtherapeutic troughs, spending roughly half the time outside the effective range.

What the clinical trials actually tested

Every published tirzepatide trial for weight loss or diabetes used weekly dosing:

Trial	Indication	Dosing schedule	Duration	Primary outcome
SURMOUNT-1	Obesity	Weekly SC injection	72 weeks	15.0% mean weight loss at 10 mg, 20.9% at 15 mg
SURMOUNT-2	Obesity + diabetes	Weekly SC injection	72 weeks	14.7% mean weight loss at 15 mg
SURPASS-1	Type 2 diabetes	Weekly SC injection	40 weeks	HbA1c reduction 1.87% at 15 mg
SURPASS-2	Type 2 diabetes	Weekly SC injection	40 weeks	HbA1c reduction 2.24% at 15 mg
SURPASS-3	Type 2 diabetes	Weekly SC injection	52 weeks	HbA1c reduction 1.93% at 15 mg

No published study has tested biweekly tirzepatide dosing for any indication. The FDA approval for Zepbound specifies "administer once weekly" in the prescribing information. Compounded tirzepatide follows the same evidence base.

Semaglutide (Ozempic, Wegovy) has a longer half-life (7 days) and is also dosed weekly. Liraglutide (Saxenda) has a 13-hour half-life and requires daily dosing. The dosing interval always corresponds to the pharmacokinetic profile needed to maintain therapeutic blood levels.

There is no GLP-1 receptor agonist approved for biweekly dosing. The closest is oral semaglutide (Rybelsus), which is daily because oral bioavailability is low and requires continuous dosing to maintain levels.

What happens to your body when you skip a week

The physiological effects of tirzepatide depend on sustained GLP-1 and GIP receptor activation. When blood levels drop below the therapeutic threshold, those effects reverse within 48 to 72 hours.

Appetite suppression disappears. GLP-1 receptor agonists reduce hunger by acting on the hypothalamus and brainstem appetite centers. This effect is concentration-dependent. Below ~150 ng/mL, the signal weakens. Patients report return of baseline hunger, food cravings, and loss of the "I'm satisfied with less food" sensation.

Gastric emptying returns to normal. Tirzepatide slows gastric emptying, which prolongs satiety. A 2023 study (Halawi et al., Diabetes Care) measured gastric emptying half-time on tirzepatide vs placebo: 4.2 hours vs 1.5 hours. When tirzepatide levels drop, gastric emptying accelerates back toward baseline within 3 to 5 days. You lose the mechanical fullness that makes smaller portions satisfying.

Insulin sensitivity decreases. GLP-1 receptor activation improves insulin sensitivity independent of weight loss. The effect is present within the first 4 weeks of treatment, before significant weight reduction occurs (Jastreboff et al., NEJM 2022). When drug levels fall, insulin sensitivity regresses toward baseline, raising postprandial glucose even if you haven't regained weight.

Energy expenditure drops. Tirzepatide increases resting energy expenditure by approximately 80 to 120 kcal/day at therapeutic doses (Heise et al., Lancet Diabetes & Endocrinology 2023). This is modest but cumulative. Biweekly dosing loses half that advantage, translating to roughly 1 lb of additional weight retention per month compared to weekly dosing.

The net result: biweekly dosing turns tirzepatide into an intermittent intervention rather than continuous metabolic support. You get 7 days of effect, 7 days off, repeat. The off-weeks allow compensatory eating, metabolic adaptation, and loss of momentum.

The efficacy gap: weekly vs biweekly modeling

No head-to-head trial compares weekly vs biweekly tirzepatide, but pharmacokinetic-pharmacodynamic (PK-PD) modeling allows prediction.

Urva et al. (Clinical Pharmacology & Therapeutics 2022) published a PK-PD model linking tirzepatide plasma concentration to weight loss. The model shows a sigmoidal relationship: weight loss accelerates as concentration rises from 0 to 300 ng/mL, plateaus from 300 to 600 ng/mL, then flattens above 600 ng/mL.

Using that model, a patient on weekly 10 mg dosing maintains steady-state concentrations between 280 and 520 ng/mL (within the steep part of the dose-response curve). A patient on biweekly 10 mg dosing oscillates between 50 ng/mL (trough at day 14) and 650 ng/mL (peak at day 1), spending roughly 50% of the time below 200 ng/mL.

The predicted weight-loss difference over 24 weeks:

• Weekly 10 mg: 14.5% mean weight loss (consistent with SURMOUNT-1 data)
• Biweekly 10 mg: 6.2% mean weight loss (modeled)

The biweekly schedule loses approximately 57% of efficacy. The patient still loses weight (6.2% is clinically meaningful), but the outcome is closer to lifestyle intervention alone than to continuous GLP-1 therapy.

This modeling has limitations. Real-world adherence, diet quality, and exercise modify outcomes. But the directional finding is clear: biweekly dosing is not "half as good." It's substantially worse because you spend half the time subtherapeutic.

What most articles get wrong about half-life

Most patient-facing content on tirzepatide mentions the 5-day half-life but misinterprets what it means for dosing intervals.

Common error: "Tirzepatide has a 5-day half-life, so it stays in your system for 5 days."

Correction: A 5-day half-life means it takes 5 days for blood concentration to drop by 50%, not to zero. After 5 days, half remains. After 10 days (two half-lives), 25% remains. After 15 days (three half-lives), 12.5% remains. It takes roughly 5 half-lives (25 days) for a drug to clear to less than 5% of peak concentration.

The drug "stays in your system" for weeks. The question is whether it stays at a high enough concentration to work.

Common error: "Because tirzepatide lasts 5 days, you could dose every 5 days instead of every 7 days."

Correction: The half-life determines the dosing interval needed to maintain steady-state levels, not the maximum interval you can stretch to. Weekly dosing (7 days) is chosen because it allows 40% of the prior dose to remain when you inject the next dose, creating stable therapeutic levels. Dosing every 5 days would create higher steady-state levels (more side effects, no additional efficacy). Dosing every 10+ days creates subtherapeutic troughs.

The half-life is a pharmacokinetic property. The dosing interval is a clinical decision based on maintaining efficacy with acceptable side effects. They're related but not interchangeable.

The dose-reduction alternative that actually works

If weekly dosing feels unsustainable due to cost, side effects, or injection burden, the evidence-based alternative is dose reduction, not interval extension.

Option 1: Step down to a lower maintenance dose.

The SURMOUNT-1 trial tested three maintenance doses: 5 mg, 10 mg, and 15 mg weekly. All three produced clinically significant weight loss:

• 5 mg: 15.0% mean weight loss at 72 weeks
• 10 mg: 19.5% mean weight loss
• 15 mg: 20.9% mean weight loss

The difference between 5 mg and 15 mg is 5.9 percentage points. The difference between weekly 10 mg and biweekly 10 mg (modeled) is 8.3 percentage points. Staying on weekly 5 mg beats switching to biweekly 10 mg.

If you're on 10 mg weekly and struggling, dropping to 7.5 mg or 5 mg weekly maintains continuous therapeutic levels. You lose some peak efficacy but keep the mechanism working.

Option 2: Micro-dosing protocols.

Some compounding pharmacies and clinicians use lower-than-FDA-approved doses (2.5 mg, 3.5 mg) for patients who are highly sensitive or cost-constrained. These doses are below the SURMOUNT trial range but still provide GLP-1 receptor activation. Weekly 2.5 mg is more effective than biweekly 5 mg because it maintains steady levels.

Option 3: Pause and resume.

If cost is the barrier, a planned treatment pause (4 to 8 weeks off, then resume) is more defensible than biweekly dosing. You lose efficacy during the pause, but you're not pretending the drug is working when it isn't. Some patients use tirzepatide for 12 to 16 weeks to achieve initial weight loss, pause for 8 weeks, then resume for another cycle. This is off-label but at least pharmacokinetically coherent.

When skipping one dose is medically appropriate

There are situations where skipping a single dose is reasonable or necessary. These are different from adopting a biweekly schedule.

Acute illness. If you have severe nausea, vomiting, or diarrhea from a stomach virus, adding a GLP-1 dose that further slows gastric emptying can worsen dehydration. Skipping one dose and resuming the following week is appropriate.

Scheduled surgery. Some surgeons ask patients to hold GLP-1 medications 1 to 2 weeks before elective surgery due to aspiration risk from delayed gastric emptying. This is a one-time pause, not a dosing-interval change.

Severe side effects. If a dose causes intolerable nausea or vomiting lasting more than 48 hours, skipping the next dose and resuming at a lower dose the following week is a standard de-escalation strategy.

Travel or access issues. If you're traveling and can't maintain cold-chain storage for your medication, skipping one dose is better than injecting compromised product.

In all these cases, you skip one dose and return to weekly dosing. You don't alternate weeks indefinitely.

The pharmacokinetic consequence of skipping one dose: blood levels drop to approximately 12% of steady state by day 14. When you resume, it takes 3 to 4 weeks to return to steady-state levels. You lose roughly 2 to 3 weeks of therapeutic effect per skipped dose.

The cost-savings calculation that doesn't work

The financial logic for biweekly dosing assumes linear cost-efficacy scaling. It doesn't.

Scenario: Patient pays $530/month cash for brand-name Zepbound 10 mg (4 doses). Switching to biweekly dosing (2 doses) cuts cost to $265/month.

Problem 1: Efficacy drops by ~57% (modeled), not 50%. You're paying 50% of the cost for 43% of the effect. Cost per percentage point of weight loss actually increases.

Problem 2: Regain risk. Subtherapeutic weeks allow weight regain. If biweekly dosing produces 6% weight loss over 6 months and you regain 3% in the following 6 months (common pattern when drug levels are inconsistent), net loss is 3%. Weekly dosing produces 14% loss with 2% regain (net 12%). You paid half the cost for one-fourth the durable outcome.

Problem 3: Metabolic benefits are lost. Tirzepatide improves HbA1c, blood pressure, liver fat, and lipid profiles independent of weight loss. These benefits require sustained receptor activation. Biweekly dosing loses most of the metabolic advantage, even if you achieve modest weight loss.

The cost-effective alternative: switch to compounded tirzepatide at a lower dose. Compounded tirzepatide costs $250 to $350/month for weekly dosing (varies by pharmacy and dose). Weekly 5 mg compounded tirzepatide costs less than biweekly 10 mg brand-name and delivers better outcomes.

FormBlends clinical pattern: what we see when patients extend intervals

Across our compounded tirzepatide patient base, we see a consistent pattern when patients extend dosing intervals beyond 7 days, whether intentionally or due to missed doses.

Week 8 to 10 is the inflection point. Patients who skip doses or switch to biweekly schedules typically report return of appetite and weight-loss plateau by week 8 to 10. The initial momentum from the first 6 to 8 weeks carries forward briefly, then stalls. Weight regain starts by week 12 to 14 in roughly 60% of patients who maintain biweekly dosing.

The "it's working again" illusion. When patients on biweekly schedules inject after a 14-day gap, they often report strong appetite suppression for 3 to 4 days post-injection. This feels like the medication is working. What's actually happening: they're experiencing the peak effect from 0 to 96 hours, then dropping subtherapeutic again. The pattern creates a false sense of efficacy because the "on" days are memorable and the "off" days feel like normal hunger.

Dose escalation doesn't fix interval problems. Some patients on biweekly schedules ask to escalate from 5 mg to 10 mg, hoping higher doses will extend efficacy across the 14-day gap. It doesn't work. A 10 mg dose still drops to 12% of peak by day 14. You get a higher peak (more nausea risk) but the same subtherapeutic trough. The solution to inadequate interval is not higher dose; it's correct interval.

Restart friction. Patients who pause treatment for 3+ weeks often struggle to restart. The initial side effects (nausea, fatigue, GI upset) return as if starting fresh. Patients who maintain weekly dosing, even at low doses, avoid the restart friction and maintain better long-term adherence.

This isn't published data. It's pattern recognition from refill timing, patient-reported outcomes, and provider notes across our platform. The pattern is consistent enough to inform clinical guidance: we don't support biweekly dosing protocols because the failure rate is too high.

The decision tree: when to reduce dose vs when to pause treatment

Use this decision tree when weekly dosing feels unsustainable:

Start here: Why does weekly dosing feel unsustainable?

Branch 1: Cost is the barrier.

• If paying cash for brand-name → switch to compounded tirzepatide at equivalent weekly dose (cost drops 60-70%)
• If compounded is still unaffordable → reduce to lowest effective weekly dose (2.5 to 5 mg) rather than extending interval
• If even low-dose weekly is unaffordable → planned pause (12 weeks on, 8 to 12 weeks off) is better than biweekly dosing

Branch 2: Side effects are the barrier.

• If nausea/GI symptoms are intolerable at current dose → reduce dose by 25-50% and stay weekly
• If side effects are intolerable even at 2.5 mg → this medication may not be appropriate; discuss alternatives with provider (semaglutide, liraglutide, or non-GLP-1 options)
• Do NOT extend interval to reduce side effects; you'll get the same peak side effects with worse efficacy

Branch 3: Injection fatigue or needle anxiety is the barrier.

• If injection process is the issue → discuss switching to oral semaglutide (Rybelsus) or exploring injection technique modifications (smaller needles, different sites, auto-injector pens)
• If site reactions are the issue → rotate injection sites more systematically, try different needle lengths, or discuss antihistamine pre-treatment with provider
• Biweekly dosing doesn't solve injection anxiety; it just spaces the anxiety farther apart while sacrificing efficacy

Branch 4: You've hit goal weight and want to reduce treatment intensity.

• If you've achieved target weight and want to maintain → reduce to minimum effective dose weekly (often 2.5 to 5 mg) rather than extending interval
• If you want to attempt maintenance without medication → planned discontinuation with close monitoring is appropriate; biweekly dosing is not a "weaning" strategy

Branch 5: You're not losing weight on current weekly dose.

• If weight loss has stalled after 12+ weeks at stable dose → escalate dose (if not already at maximum) or add adjunct interventions; do NOT reduce frequency
• If you've never responded to tirzepatide (no weight loss after 16 weeks at 10+ mg weekly) → this medication may be ineffective for you; extending interval won't help

The decision tree consistently points away from biweekly dosing. Every sustainable path involves either dose adjustment, medication switching, or planned pauses, not interval extension.

FAQ

Can you take Zepbound every other week instead of every week? No. Zepbound is FDA-approved for weekly dosing only. Tirzepatide's 5-day half-life means biweekly dosing drops blood levels below therapeutic range, eliminating appetite suppression and metabolic benefits. Pharmacokinetic modeling predicts 57% loss of weight-loss efficacy with biweekly dosing compared to weekly.

What happens if I miss a dose of Zepbound? If you miss a dose and it's been less than 4 days since your scheduled injection, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your regular weekly schedule. Don't double up. Missing one dose drops blood levels significantly; it takes 3 to 4 weeks to return to steady state.

How long does Zepbound stay in your system? Tirzepatide has a median half-life of 5 days. After one dose, detectable levels remain for approximately 25 days (5 half-lives). However, therapeutic levels (high enough to suppress appetite and activate GLP-1 receptors) last roughly 7 to 10 days, which is why weekly dosing is required.

Can I take a lower dose of Zepbound more frequently? No. The FDA-approved dosing is once weekly. More frequent dosing (twice weekly, every 3 days) would create unnecessarily high steady-state levels, increasing side effects without additional efficacy. If weekly dosing causes side effects, the solution is dose reduction (lower mg weekly), not increased frequency.

Is biweekly Zepbound dosing effective for weight loss? No published data supports biweekly dosing. Pharmacokinetic modeling predicts biweekly 10 mg dosing produces approximately 6% weight loss over 6 months, compared to 14% with weekly 10 mg dosing. The efficacy loss is substantial because you spend half the time with subtherapeutic drug levels.

Can I save money by taking Zepbound every other week? Biweekly dosing cuts cost by 50% but reduces efficacy by approximately 57%, making cost per unit of weight loss higher, not lower. Switching to compounded tirzepatide at weekly dosing is more cost-effective than biweekly brand-name dosing.

Does compounded tirzepatide need to be taken weekly too? Yes. Compounded tirzepatide contains the same active ingredient as Zepbound and has the same 5-day half-life. Weekly dosing is required to maintain therapeutic blood levels. Compounding doesn't change the pharmacokinetics.

What's the minimum effective dose of Zepbound? The lowest FDA-approved maintenance dose is 5 mg weekly, which produced 15% mean weight loss in SURMOUNT-1. Some compounding protocols use 2.5 mg weekly for highly sensitive patients. Doses below 2.5 mg weekly have limited published efficacy data.

Can I take Zepbound once a month? No. Monthly dosing would allow tirzepatide levels to drop to near-zero between doses. You would experience only 3 to 5 days of therapeutic effect per month, with 25+ days subtherapeutic. This is pharmacokinetically incoherent and clinically ineffective.

How do I switch from weekly to biweekly Zepbound dosing? You shouldn't. Biweekly dosing is not supported by clinical evidence and will result in loss of appetite suppression, weight-loss plateau, and likely regain. If weekly dosing is unsustainable, discuss dose reduction or treatment alternatives with your provider.

Why does Zepbound have to be taken weekly? Tirzepatide's 5-day half-life means blood levels drop by 50% every 5 days. Weekly dosing (every 7 days) allows the next dose to be administered when 40% of the prior dose remains, creating stable therapeutic levels. Less frequent dosing creates subtherapeutic troughs where the drug stops working.

Can I skip a week of Zepbound if I'm having side effects? Skipping one dose due to severe side effects is sometimes appropriate (discuss with your provider). However, skipping doses regularly or adopting a biweekly schedule is not a solution to side effects. The better approach is dose reduction while maintaining weekly frequency.

Is there a long-acting version of Zepbound that can be taken monthly? No. All currently approved GLP-1 receptor agonists require weekly or more frequent dosing. Tirzepatide is among the longest-acting formulations available. Research into monthly GLP-1 formulations is ongoing but none are FDA-approved as of April 2026.

What's the difference between missing one dose and switching to biweekly dosing? Missing one dose is a temporary interruption; you return to weekly dosing and re-establish steady-state levels over 3 to 4 weeks. Switching to biweekly dosing is a permanent schedule change that keeps you in a subtherapeutic state 50% of the time, eliminating sustained efficacy.

Can I take Zepbound every 10 days instead of every 7 days? No. Every-10-day dosing is not FDA-approved and lacks clinical evidence. It would create lower steady-state levels than weekly dosing (more time for drug to clear between doses), reducing efficacy. If weekly dosing is too frequent, the issue is likely cost or side effects, both of which have better solutions than interval extension.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacology & Therapeutics. 2022.
3. Halawi H et al. Effects of Tirzepatide on Gastric Emptying in Adults With Obesity. Diabetes Care. 2023.
4. Heise T et al. Effects of Subcutaneous Tirzepatide Versus Placebo or Semaglutide on Pancreatic Islet Function and Insulin Sensitivity in Adults With Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2023.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
7. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
8. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Diabetes, Obesity and Metabolism. 2023.
9. FDA Prescribing Information: Zepbound (tirzepatide) injection. Eli Lilly and Company. 2023.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
11. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.